Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C

Inclusion criteria: * Liver transplantation performed at least 6 months and up to 5 years prior randomization and due to HCV cirrhosis, with or without pre-transplant hepatocellular carcinoma (HCC) within Milan or UCSF criteria * Immunosuppresive regimen based on tacrolimus b.i.d.- (twice or once daily) for at least 6 months prior randomization * Diagnosis of HCV genotypes 1 or 4 infection prior to transplantationconfirmed at screening * Indication of treatment with Peg-IFN and ribavirin due to histological evidence of chronic HCV infection defined as a fibrosis stage equal or greater than 1 using the Ishak-Knodell scoring system (IK ≥1) in a liver biopsy performed at screening or up to 4 months prior to randomization. Exclusion criteria: * Serum creatinine \>150 μmol/L (1.6 7 mg/dL) or eGFR \< 50 ml/min (4-variable Modification of Diet in Renal Disease \[MDRD Cockcroft-Gault formula\]) * Multi-organ transplant recipients * Recent episode of steroid-treated acute rejection (AR) within 3 months prior to randomization, or \>1 episode of steroid-treated AR in the last 6 months, or any number of steroid-resistant AR episodes in the last 6 months including evidence of chronic rejection or ductopenia * Evidence of conditions that could cause graft dysfunction other than HCV infection * Patients with signs of decompensated liver disease, defined as presence of ascites, variceal bleeding, encephalopathy or deteriorated hepatic synthetic function (albumin \<3.5g/dL or, total direct bilirubin \>1.5mg/dL or, INR \>1.5) * Co-infection with HIV or Hepatitis B (defined as HBsAg-positive) at screening * Use of mTOR inhibitors (everolimus or sirolimus) in the 6 months prior to screening * Antiviral treatment for HCV administered at any time after liver transplantation * Patients on daily doses of corticosteroids higher than 5 mg/day * Patients with fibrosing cholestatic hepatitis * Patients with current diagnosis of malignancies, including lymphoproliferative disorders * Patients with platelet count \<70,000/mm3 or neutrophiles \<1,500/mm3 * History of HCC outside Milan criteria based on radiology or UCSF criteria based on analysis of the explant